BioForce Nanosciences Holdings, Inc. Completes $6 Million Private Placement

Mar 21, 2006, 00:00 ET from BioForce Nanosciences Holdings, Inc.

    AMES, Iowa, March 21 /PRNewswire-FirstCall/ -- BioForce Nanosciences
 Holdings, Inc. ("BioForce"), (OTC Bulletin Board:   BFNH), today announced that
 it has closed a $6 million Private Placement of restricted common shares
 @$1.50/share. The company's shares trade under the symbol BFNH.
     Dr. Eric Henderson, BioForce founder and CEO and an early developer of
 nanotechnology tools, said, "With this financing, and the recent addition of
 key senior management, BioForce is well positioned to take full advantage of
 the commercial opportunities that our NanoArrayer(TM) System provides. This
 funding will also facilitate continued development of the company's pipeline
     BioForce's core technology, the NanoArrayer(TM) System, is a proprietary
 instrumentation and software tool that is poised to impact multiple areas in
 the life sciences. The NanoArrayer(TM) is a new and enabling platform for
 addressing previously intractable research problems, thereby enhancing the
 opportunity for scientific breakthroughs.
     The company is also commercializing a patented diagnostic device called
 the ViriChip(TM) System, which is used for detection and identification of
 multiple viruses and other pathogens simultaneously on a single chip. The
 ViriChip(TM) is a consumable product that creates a recurring revenue
     About BioForce Nanosciences Holdings, Inc.
     BioForce creates products that enable future advances in nanotechnology
 across a broad spectrum of industries. The company has developed, patented and
 initiated commercialization of a unique instrument called the NanoArrayer(TM).
 The NanoArrayer(TM) is a tabletop device with the ability to print and pattern
 thousands of molecular domains on a chip in an extremely miniaturized format.
 Another emphasis of the company is the patented ViriChip(TM) System for the
 direct, non-destructive and simultaneous detection and identification of
 multiple viruses. BioForce is synergistically expanding its technology
 foundation with a pipeline of additional tools and devices through both
 internal and external growth. The company's founder and CEO, Dr. Eric
 Henderson, is a pioneer in the application of nanotechnology to life sciences
 research and development.
     This news release may contain certain forward-looking statements within
 the meaning of applicable securities laws. Forward-looking statements are
 based on current expectations and the current economic environment. Readers
 are cautioned not to put undue reliance on such forward-looking statements.
 Unknown risks and uncertainties, including those described in the company's
 most recent filings with the Securities and Exchange Commission, may cause
 actual results to differ materially from those contained in forward-looking
 statements. The forward-looking statements are made only as of the date of
 this news release and the company assumes no duty to publicly update these
 statements to reflect subsequent events or circumstances.

SOURCE BioForce Nanosciences Holdings, Inc.